Previous 10 | Next 10 |
MALVERN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today ann...
Galera Therapeutics (NASDAQ:GRTX): Q3 GAAP EPS of -$0.86 misses by $0.15. Cash, cash equivalents and short-term investments of $88.7M Press Release For further details see: Galera Therapeutics EPS misses by $0.15
Recently announced topline results of Phase 3 ROMAN trial of avasopasem for radiotherapy-induced severe oral mucositis Enrollment ongoing in GRECO-1 and GRECO-2 trials of rucosopasem (GC4711) in combination with SBRT in patients with NSCLC and pancreatic cancer; initial data fro...
HCW Biologics (NASDAQ:HCWB) +102% after FDA greenlight for HCW9218 pancreatic cancer study InflaRx (NASDAQ:IFRX) +61% as Raymond James upgrades expecting price to quadruple LendingClub (NYSE:LC) +32% on Q3 earnings. DatChat (NASDAQ:DATS) +15% launches social...
Gainers: Camber Energy (NYSE:CEI) +27%. HCW Biologics (NASDAQ:HCWB) +21%. Fuel Tech (NASDAQ:FTEK) +23%. RedHill (NASDAQ:RDHL) +19%. Harmony (NASDAQ:HRMY) +15%. Ginkgo Bioworks (NYSE:DNA) +15%. Arqit Quantum (NASDAQ:ARQQ) +14%. AlloVir (NASDAQ:ALVR) +13%. ViewRay (NASDAQ:VRAY) +13%. Full Truck...
Gainers: AlloVir (NASDAQ:ALVR) +14%, InflaRx (NASDAQ:IFRX) +14%, Harmony Biosciences (NASDAQ:HRMY) +13%, Omeros (NASDAQ:OMER) +11%, Prelude Therapeutics (NASDAQ:PRLD) +11%. Losers: Galera Therapeutics (NASDAQ:GRTX) -68%, Atea Pharmaceutic...
Shares of Galera Therapeutics Inc ( NASDAQ: GRTX ) tanked 73% on Tuesday after the company said its Avasopasem trial did not meet the primary endpoint. Avasopasem does not ‘significantly’ reduce the incidence of SOM Galera was running a Phase III trial for Avas...
Primary endpoint of reduction in incidence of severe oral mucositis (SOM) not met Trial demonstrated relative reduction in all key SOM endpoints, including more than halving the median duration Avasopasem was generally well tolerated compared to placebo MALVERN, Pa...
Event to be webcast on Thursday, September 23 at 11:00 a.m. ET Phase 3 ROMAN trial of avasopasem manganese, Galera’s lead candidate for SOM in patients with head and neck cancer, expected to read out in 4Q 2021 MALVERN, Pa., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Galera...
Improvements observed in overall survival, progression-free survival, local tumor control, time to metastases, and tumor response rate Hazard ratios better than 0.5 on all survival and tumor outcome endpoints Combination with SBRT was well tolerated in the active and pla...
News, Short Squeeze, Breakout and More Instantly...
Galera Therapeutics Inc. Company Name:
GRTX Stock Symbol:
NYSE Market:
Galera Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Nauticus Robotics Inc. (KITT) rose 29.5% to $0.1787 on volume of 92,016,620 shares Freight Technologies Inc. (FRGT) rose 92.0% to $1.2 on volume of 65,878,105 shares Aethlon Medical Inc. (AEMD) rose 68.2% to $0.7379 on volume of 48,98...
A look at the top 10 most actives in the United States ENDRA Life Sciences Inc. (NDRA) rose 88.2% to $0.159999 on volume of 216,555,450 shares Crown Electrokinetics Corp. (CRKN) fell 13.1% to $0.0908 on volume of 52,298,971 shares Actelis Networks Inc (ASNS) rose 591.5% to $3.25 on volume...
A look at the top 10 most actives in the United States SOBR Safe Inc. (SOBR) rose 74.6% to $0.46 on volume of 265,324,361 shares MicroAlgo Inc. (MLGO) rose 669.9% to $12.01 on volume of 183,977,846 shares PROSHARES TRUST (SQQQ) fell 0.7% to $9.86 on volume of 124,114,596 shares Faraday ...